Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
EP300
REST API REST API
Homo sapiens
EP300 is differentially expressed in 271 experiments: 112 organism parts: ovary, placenta, ... (110 more);, 179 disease states: normal, acute myeloid leukemia, ... (177 more);, 90 cell types 409 cell lines 39 compound treatments and 71 other conditions.
Synonyms p300, KAT3B
Orthologs EP300 (Gallus gallus)   ENSCING00000009030 (Ciona intestinalis)   F1LPY5_RAT (Rattus norvegicus)   ENSCING00000017171 (Ciona intestinalis)   Ep300 (Mus musculus)   EP300 (Bos taurus)   ep300a (Danio rerio)   ep300b (Danio rerio)   BDF1 (Saccharomyces cerevisiae)   BDF2 (Saccharomyces cerevisiae)   Q28E87_XENTR (Xenopus laevis)   EP300 (Canis familiaris)   nej (Drosophila melanogaster)   (Compare orthologs)
Gene Ontology Term response to hydrogen peroxide, DNA binding, protein binding, apoptosis, positive regulation of translation, histone acetyltransferase activity, positive regulation of protein secretion, regulation of transcription, DNA-dependent, lysine N-acetyltransferase activity, cytoplasm, beta-catenin binding, acetyltransferase activity, innate immune response, transcription, DNA-dependent, positive regulation of gene expression, protein-DNA complex assembly, metal ion binding, response to hypoxia, somitogenesis, positive regulation of cell size, transcription factor binding, protein kinase B signaling cascade, cell cycle, histone acetyltransferase complex, positive regulation of transcription from RNA polymerase II promoter, centrosome, transcription coactivator activity, DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis, transcription cofactor activity, protein kinase binding, nucleus, heart development, histone acetylation, chromatin DNA binding, transcription factor complex, response to drug, nervous system development, positive regulation of cell growth, chromatin, nucleoplasm, response to ethanol, skeletal muscle tissue development, positive regulation of transcription, DNA-dependent, organ morphogenesis, digestive tract development, positive regulation of proteolysis, zinc ion binding, transferase activity, transferring acyl groups, glucocorticoid receptor binding, androgen receptor binding, antigen binding, regulation of androgen receptor signaling pathway, response to calcium ion, positive regulation of collagen biosynthetic process, peroxisome proliferator activated receptor binding, positive regulation of protein import into nucleus, translocation, N-terminal peptidyl-lysine acetylation, positive regulation by host of viral transcription, regulation of angiotensin metabolic process, positive regulation of DNA binding, response to cobalt ion, response to estrogen stimulus, protein-DNA complex, response to fatty acid, positive regulation of axon extension, positive regulation of glycoprotein biosynthetic process, response to retinoic acid, negative regulation of cellular metabolic process, positive regulation of cellular metabolic process, interspecies interaction between organisms, NF-kappaB binding, cellular response to hydrogen peroxide, lung development, internal peptidyl-lysine acetylation, liver development, response to glucose stimulus, protein complex binding, positive regulation of protein binding, response to glucocorticoid stimulus, mitogen-activated protein kinase binding, positive regulation of sarcomere organization, histone H4 acetylation, sequence-specific DNA binding transcription factor activity, activating transcription factor binding, positive regulation of protein phosphorylation, RNA polymerase II core promoter proximal region sequence-specific DNA binding, response to organic cyclic compound, RNA polymerase II activating transcription factor binding, RNA polymerase II transcription factor binding, positive regulation of sequence-specific DNA binding transcription factor activity
InterPro Term DUF902_CREBbp, Znf_TAZ, Bromodomain, Znf_ZZ, KIX, Nuc_rcpt_coact_CREBbp, Histone_H3-K56_AcTrfase_RTT109
UniProt Accession Q09472, B5A250
Gene-Disease Assocation COLORECTAL CANCER; CRC, RUBINSTEIN-TAYBI SYNDROME 2; RSTS2, RUBINSTEIN-TAYBI SYNDROME 1; RSTS1
Search EB-eye ENSG00000100393
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-GEOD-7540, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (35 experiments)

Factor Value U/D Experiments
MDA-MB-231
3
E-GEOD-5823, E-TABM-420, E-MTAB-62
MCF-7
1
3
E-GEOD-5823, E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
MCF7
2
E-MTAB-37, E-GEOD-5258
BT474
2
E-MTAB-62, E-MEXP-440
DU145
2
E-GEOD-17482, E-GEOD-20089
HL-60
2
E-MTAB-37, E-GEOD-5258
403 more value(s).


Cell type

studied in E-GEOD-22373, E-MEXP-750, E-MEXP-66, E-GEOD-4219, E-GEOD-13909, ... (42 experiments)

Factor Value U/D Experiments
CD33+ myeloid
1
2
E-AFMX-5, E-TABM-145
adipocyte
2
E-TABM-145, E-AFMX-5
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
plasma cell
2
E-MEXP-2360, E-GEOD-6691
CD71+ early erythroid
2
E-AFMX-5, E-TABM-145
monocyte
2
3
E-MEXP-583, E-GEOD-11755, E-GEOD-22373, E-GEOD-8286, E-GEOD-5099 ... (5 experiments)
84 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MEXP-1121, E-GEOD-16363, ... (49 experiments)

Factor Value U/D Experiments
healthy
2
E-GEOD-14895, E-GEOD-19188
Burkitt's lymphoma
2
E-MTAB-37, E-GEOD-96
malignant peripheral nerve sheath tumor
2
E-MTAB-62, E-GEOD-6481
prostate carcinoma
2
E-MTAB-62, E-GEOD-5377
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
lymphoma
1
E-MTAB-37
173 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-3720, E-GEOD-5824, E-GEOD-5099, E-MEXP-1958, ... (23 experiments)

Factor Value U/D Experiments
none
2
5
E-GEOD-20719, E-GEOD-412, E-GEOD-5824, E-MEXP-1958, E-GEOD-7307, ... (7 experiments)
unknown
1
E-GEOD-7307
mannitol
1
E-GEOD-6400
Cxcl12
1
E-GEOD-7307
hydroxyurea
1
E-GEOD-6431
sapphyrin PCI-2052
1
E-GEOD-6400
33 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
41
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-2171, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-TABM-176, E-GEOD-19348, E-GEOD-860, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-MEXP-2359, E-GEOD-6236, E-GEOD-4667, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-GEOD-22148, E-TABM-147, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, E-GEOD-6431, ... (6 experiments)

Genotype
studied in E-MEXP-1996, E-TABM-1029, E-GEOD-1045, E-MEXP-149, E-GEOD-17476, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, E-TABM-127, ... (8 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-26, ... (41 experiments)

individual id
studied in E-GEOD-19519

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-GEOD-17400

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-26495, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-15811, E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290

Vehicle
studied in E-GEOD-5258

Processing time: 0.462 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM